We are live on ! Find out more
DMRA

Damora Therapeutics
DMRA

9 hedge funds and large institutions have $451K invested in Damora Therapeutics in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $442K → $451K (+$9.12K)

0.77% less ownership

Funds ownership: 10.81% → 10.04% (-0.77%)

18% less funds holding

Funds holding: 11 → 9 (-2)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$8.52K
2
UBS Group
UBS Group
Switzerland
+$6K
3
Bank of America
Bank of America
North Carolina
+$6

Top Sellers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
-$40.3K
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.37K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.9K
4
BlackRock
BlackRock
New York
-$1.15K
5
Barclays
Barclays
United Kingdom
-$98

DMRA Hedge Fund Activity: Q2 2025 in Review

9 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q2 2025, worth a combined $451K — up 2.1% from $442K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of DMRA and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, adding an estimated $8.52K. The largest seller was Squarepoint, exiting entirely with an estimated $40.3K sold.

  • 9 institutional investors held Damora Therapeutics (DMRA) as of Q2 2025, down from 11 in Q1 2025.
  • Funds reported $451K of Damora Therapeutics stock for Q2 2025, up 2.1% quarter-over-quarter.
  • 0 funds opened new Damora Therapeutics positions in Q2 2025 and 2 closed out, a net change of -2 holders.
  • The largest Damora Therapeutics buyer in Q2 2025 was Susquehanna International Group, an estimated $8.52K added.
  • The largest Damora Therapeutics seller in Q2 2025 was Squarepoint, an estimated $40.3K sold.

Based on aggregated 13F filings for Q2 2025.